Pages Menu
Categories Menu

Posted by on Apr 11, 2008 in CME, Ethics, Pharma

SP to Grassley: Here’s Your Disclosure, Right Here

SP to Grassley: Here’s Your Disclosure, Right Here

Moving through this morning’s pharma blogosphere is an AP story describing the responses of some drug or medical-device companies to Senator Chuck Grassley’s request that they disclose their CME funding to outside groups. The current industry model is that of Eli Lilly, which provides a highly itemized (and therefore, very difficult-to-synthesize) online grants registry report for each financial quarter of 2007.

Among the companies’ soup-to-nuts replies to Grassley:

  • Medtronic will post payments for professional meetings and patient groups on May 1 (no mention of funds to medical communications companies);
  • AstraZeneca will do the same on August 1;
  • Merck is “currently in the process of developing an action plan”;
  • Amgen and Abbott have formed “working groups”; and
  • nose-thumbing Schering-Plough reports that it has no plans “at the moment” to publish the requested information.

Today’s WSJ Health Blog notes that Grassley’s also sponsoring the Physician Payments Sunshine* Act of 2007, which will require quarterly reports from drug or medical-device companies to the DHHS regarding payments made to individual physicians or their employers.

CME = continuing medical education.

*As in, blow sunshine up my…?

bmartin (1127 Posts)

A native East Tennessean, Barbara Martin is a formerly practicing, board-certified neurologist who received her BS (psychology, summa cum laude) and MD from Duke University before completing her postgraduate training (internship, residency, fellowship) at the Hospital of the University of Pennsylvania in Philadelphia. She has worked in academia, private practice, medical publishing, drug market research, and continuing medical education (CME). For the last 3 years, she has worked in a freelance capacity as a medical writer, analyst, and consultant. Follow Dr. Barbara Martin on and Twitter.